» Articles » PMID: 36226598

The Psychotomimetic Ketamine Disrupts the Transfer of Late Sensory Information in the Corticothalamic Network

Overview
Journal Eur J Neurosci
Specialty Neurology
Date 2022 Oct 13
PMID 36226598
Authors
Affiliations
Soon will be listed here.
Abstract

In prodromal and early schizophrenia, disorders of attention and perception are associated with structural and chemical brain abnormalities and with dysfunctional corticothalamic networks exhibiting disturbed brain rhythms. The underlying mechanisms are elusive. The non-competitive NMDA receptor antagonist ketamine simulates the symptoms of prodromal and early schizophrenia, including disturbances in ongoing and task & sensory-related broadband beta-/gamma-frequency (17-29 Hz/30-80 Hz) oscillations in corticothalamic networks. In normal healthy subjects and rodents, complex integration processes, like sensory perception, induce transient, large-scale synchronised beta/gamma oscillations in a time window of a few hundred ms (200-700 ms) after the presentation of the object of attention (e.g., sensory stimulation). Our goal was to use an electrophysiological multisite network approach to investigate, in lightly anesthetised rats, the effects of a single psychotomimetic dose (2.5 mg/kg, subcutaneous) of ketamine on sensory stimulus-induced oscillations. Ketamine transiently increased the power of baseline beta/gamma oscillations and decreased sensory-induced beta/gamma oscillations. In addition, it disrupted information transferability in both the somatosensory thalamus and the related cortex and decreased the sensory-induced thalamocortical connectivity in the broadband gamma range. The present findings support the hypothesis that NMDA receptor antagonism disrupts the transfer of perceptual information in the somatosensory cortico-thalamo-cortical system.

Citing Articles

Auditory steady-state response deficits in Fragile X Syndrome implicate deficits in stimulus representation maintenance and GABAergic modulation.

Norris J, De Stefano L, McKinney W, Schmitt L, Miyakoshi M, Gross C medRxiv. 2025; .

PMID: 39973986 PMC: 11838689. DOI: 10.1101/2025.01.29.25321365.


Immediate and long-term electrophysiological biomarkers of antidepressant-like behavioral effects after subanesthetic ketamine and medial prefrontal cortex deep brain stimulation treatment.

Bergosh M, Medvidovic S, Zepeda N, Crown L, Ipe J, Debattista L Front Neurosci. 2024; 18:1389096.

PMID: 38966758 PMC: 11222339. DOI: 10.3389/fnins.2024.1389096.


Ketamine: Linking NMDA receptor hypofunction, gamma oscillations and psychosis (commentary on Qin et al., 2022).

Reilly T Eur J Neurosci. 2022; 57(3):456-457.

PMID: 36442864 PMC: 10107757. DOI: 10.1111/ejn.15872.


The psychotomimetic ketamine disrupts the transfer of late sensory information in the corticothalamic network.

Qin Y, Mahdavi A, Bertschy M, Anderson P, Kulikova S, Pinault D Eur J Neurosci. 2022; 57(3):440-455.

PMID: 36226598 PMC: 10092610. DOI: 10.1111/ejn.15845.

References
1.
Homayoun H, Moghaddam B . NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons. J Neurosci. 2007; 27(43):11496-500. PMC: 2954603. DOI: 10.1523/JNEUROSCI.2213-07.2007. View

2.
Mayeli A, LaGoy A, Donati F, Kaskie R, Najibi S, Ferrarelli F . Sleep abnormalities in individuals at clinical high risk for psychosis. J Psychiatr Res. 2021; 137:328-334. PMC: 8085028. DOI: 10.1016/j.jpsychires.2021.03.006. View

3.
Hong L, Summerfelt A, Buchanan R, ODonnell P, Thaker G, Weiler M . Gamma and delta neural oscillations and association with clinical symptoms under subanesthetic ketamine. Neuropsychopharmacology. 2009; 35(3):632-40. PMC: 3055615. DOI: 10.1038/npp.2009.168. View

4.
Knyazev G . EEG delta oscillations as a correlate of basic homeostatic and motivational processes. Neurosci Biobehav Rev. 2011; 36(1):677-95. DOI: 10.1016/j.neubiorev.2011.10.002. View

5.
Sarton E, Teppema L, Olievier C, Nieuwenhuijs D, Matthes H, Kieffer B . The involvement of the mu-opioid receptor in ketamine-induced respiratory depression and antinociception. Anesth Analg. 2001; 93(6):1495-500, table of contents. DOI: 10.1097/00000539-200112000-00031. View